Ultima Genomics

Executive Summary

Ultima Genomics is a private U.S. biotechnology company that aims to democratize high-throughput DNA sequencing with its UG200™ platform. By delivering dramatically higher output and lower cost per genome in a compact instrument footprint, the company targets population-scale genomics applications, including large cohort studies, clinical diagnostics, and agricultural genomics. Ultima’s technology addresses the need for affordable, scalable sequencing, positioning it as a key player in the rapidly expanding genomics market, which is projected to exceed $50 billion by 2030. The company’s differentiated approach—using novel biochemistry and simplified workflows—could enable sequencing at under $100 per genome, unlocking broad adoption in research and clinical settings. While still private and early-stage, Ultima’s disruptive potential has attracted interest from leading genomics researchers and investors.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of UG200 or next-gen platform70% success
• Q2 2026Strategic partnership with major research institution or genome center65% success
• Q3 2026Series C or later funding round announcement80% success